Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
$3.12
-7.4%
$4.97
$0.24
$1.49
$46.40M2.82127,174 shs23,389 shs
InnovAge Holding Corp. stock logo
INNV
InnovAge
$4.00
-0.7%
$4.63
$3.82
$8.05
$543.60M0.1523,535 shs16,354 shs
International Stem Cell Co. stock logo
ISCO
International Stem Cell
$0.07
$0.09
$0.05
$0.19
N/A0.511,332 shsN/A
Praxsyn Co. stock logo
PXYN
Praxsyn
$0.00
$0.00
$0.01
$85K-1.01N/AN/A
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
-7.42%-11.61%-30.04%-1.89%+358.15%
InnovAge Holding Corp. stock logo
INNV
InnovAge
-0.74%-2.20%-14.16%-31.03%+399,999,900.00%
International Stem Cell Co. stock logo
ISCO
International Stem Cell
0.00%+0.14%+36.66%-40.42%-60.44%
Praxsyn Co. stock logo
PXYN
Praxsyn
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
InnovAge Holding Corp. stock logo
INNV
InnovAge
0.825 of 5 stars
3.02.00.00.01.80.00.6
International Stem Cell Co. stock logo
ISCO
International Stem Cell
N/AN/AN/AN/AN/AN/AN/AN/A
Praxsyn Co. stock logo
PXYN
Praxsyn
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
N/AN/AN/AN/A
InnovAge Holding Corp. stock logo
INNV
InnovAge
2.00
Hold$6.5062.50% Upside
International Stem Cell Co. stock logo
ISCO
International Stem Cell
N/AN/AN/AN/A
Praxsyn Co. stock logo
PXYN
Praxsyn
N/AN/AN/AN/A

Current Analyst Ratings

Latest ISCO, GEMP, PXYN, and INNV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/13/2024
InnovAge Holding Corp. stock logo
INNV
InnovAge
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$7.00 ➝ $6.00
2/8/2024
InnovAge Holding Corp. stock logo
INNV
InnovAge
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$8.00 ➝ $7.00
(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
N/AN/AN/AN/A$0.54 per shareN/A
InnovAge Holding Corp. stock logo
INNV
InnovAge
$688.09M0.79N/AN/A$2.23 per share1.79
International Stem Cell Co. stock logo
ISCO
International Stem Cell
$7.79MN/AN/AN/A($0.57) per shareN/A
Praxsyn Co. stock logo
PXYN
Praxsyn
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
-$23.64MN/A0.00N/AN/A-419.70%-173.05%N/A
InnovAge Holding Corp. stock logo
INNV
InnovAge
-$40.67M-$0.25N/A400.00N/A-4.38%-10.53%-5.69%5/14/2024 (Estimated)
International Stem Cell Co. stock logo
ISCO
International Stem Cell
-$130K-$0.03N/AN/A-2.68%-2.80%-3.77%N/A
Praxsyn Co. stock logo
PXYN
Praxsyn
N/AN/A0.00N/AN/AN/AN/AN/AN/A

Latest ISCO, GEMP, PXYN, and INNV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/28/2024Q4 2023
International Stem Cell Co. stock logo
ISCO
International Stem Cell
N/A-$0.04-$0.04-$0.04N/A$1.89 million
2/5/2024Q2 2024
InnovAge Holding Corp. stock logo
INNV
InnovAge
-$0.03-$0.03N/A-$0.03$181.51 million$188.90 million      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
N/AN/AN/AN/AN/A
InnovAge Holding Corp. stock logo
INNV
InnovAge
N/AN/AN/AN/AN/A
International Stem Cell Co. stock logo
ISCO
International Stem Cell
N/AN/AN/AN/AN/A
Praxsyn Co. stock logo
PXYN
Praxsyn
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
N/A
0.67
0.67
InnovAge Holding Corp. stock logo
INNV
InnovAge
0.26
1.27
1.27
International Stem Cell Co. stock logo
ISCO
International Stem Cell
N/A
0.73
0.47
Praxsyn Co. stock logo
PXYN
Praxsyn
N/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
17.53%
InnovAge Holding Corp. stock logo
INNV
InnovAge
12.26%
International Stem Cell Co. stock logo
ISCO
International Stem Cell
N/A
Praxsyn Co. stock logo
PXYN
Praxsyn
N/A

Insider Ownership

CompanyInsider Ownership
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
22.70%
InnovAge Holding Corp. stock logo
INNV
InnovAge
0.41%
International Stem Cell Co. stock logo
ISCO
International Stem Cell
67.97%
Praxsyn Co. stock logo
PXYN
Praxsyn
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
914.87 millionN/ANot Optionable
InnovAge Holding Corp. stock logo
INNV
InnovAge
2,100135.90 million135.34 millionOptionable
International Stem Cell Co. stock logo
ISCO
International Stem Cell
29N/AN/ANot Optionable
Praxsyn Co. stock logo
PXYN
Praxsyn
66847.94 millionN/ANot Optionable

ISCO, GEMP, PXYN, and INNV Headlines

SourceHeadline
PXYN.PK - Praxsyn Corp | Stock Price & Latest News | ReutersPXYN.PK - Praxsyn Corp | Stock Price & Latest News | Reuters
reuters.com - August 13 at 8:46 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Gemphire Therapeutics logo

Gemphire Therapeutics

NASDAQ:GEMP
Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company is developing gemcabene, a novel, once-daily, and oral therapy for dyslipidemia conditions where patients are unable to reach their lipid lowering goals, including patients already receiving maximally tolerated statin therapy. It also completed three Phase IIb clinical trials for gemcabene in homozygous familial hypercholesterolemia (HoFH) and hypercholesterolemia, including heterozygous familial hypercholesterolemic (HeFH) and atherosclerotic cardiovascular disease (ASCVD) patients on maximally tolerated statins, and severe hypertriglyceridemia (SHTG). The company was founded in 2008 and is headquartered in Livonia, Michigan.
InnovAge logo

InnovAge

NASDAQ:INNV
InnovAge Holding Corp. manages and provides a range of medical and ancillary services for seniors in need of care and support to live independently in their homes and communities. The company manages its business through Program of All-Inclusive Care for the Elderly (PACE) approach. It also offers in-home care services consisting of skilled, unskilled, and personal care; in-center services, such as primary care, physical therapy, occupational therapy, speech therapy, dental services, mental health and psychiatric services, meals, and activities; transportation to the PACE center and third-party medical appointments; and care management. The company serves participants in the United States; and operates PACE centers in Colorado, California, New Mexico, Pennsylvania, and Virginia. The company was formerly known as TCO Group Holdings, Inc. and changed its name to InnovAge Holding Corp. in January 2021. InnovAge Holding Corp. was founded in 2007 and is headquartered in Denver, Colorado.
International Stem Cell logo

International Stem Cell

OTCMKTS:ISCO
International Stem Cell Corporation, a clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in the United States, Asia, Europe, and internationally. It develops ISC- hpNSC, a neural stem cell program that has completed the Phase I clinical trial for the treatment of Parkinson's disease, as well as for treating stroke and traumatic brain injury. The company also offers anti-aging skin care products, including ProPlus Advanced Defense Complex, ProPlus Advanced Recovery Complex, ProPlus Eye Firming Complex, ProPlus Neck Firming Complex, ProPlus Advanced Aqueous Treatment, ProPlus Collagen Booster, ProPlus Elastin Booster, and ProPlus Brightening Toner. In addition, it provides human cell culture products comprising human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. Its human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; human female reproductive system cells for the study of cellular physiology; human skeletal muscle cells for the study of biology, diabetes, insulin receptor studies, muscle metabolism, muscle tissue repair, and myotube development; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. International Stem Cell Corporation was founded in 2001 and is headquartered in San Diego, California.
Praxsyn logo

Praxsyn

OTCMKTS:PXYN
Praxsyn Corporation, a health care company, provides medical practitioners with medications and services for their patients. It formulates non-narcotic and non-habit forming medications using therapeutic and preventative agents in the forms of transdermal creams, patches, and oral capsules for pain management, erectile dysfunction, and metabolic therapies. Praxsyn Corporation provides its products to patients covered under the California workers' compensation system, as well as preferred provider contracts. The company was formerly known as The PAWS Pet Company, Inc. and changed its name to Praxsyn Corporation in March 2014. Praxsyn Corporation was founded in 2005 and is headquartered in Las Vegas, Nevada.